Sphera Funds Management LTD. Buys 28,265 Shares of Aerpio Pharmaceuticals Inc (ARPO)
Sphera Funds Management LTD. increased its stake in shares of Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) by 2.6% in the third quarter, Holdings Channel reports. The institutional investor owned 1,131,819 shares of the company’s stock after acquiring an additional 28,265 shares during the period. Sphera Funds Management LTD.’s holdings in Aerpio Pharmaceuticals were worth $3,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Orbimed Advisors LLC bought a new position in Aerpio Pharmaceuticals during the 2nd quarter worth $21,555,000. Millennium Management LLC bought a new position in Aerpio Pharmaceuticals during the 2nd quarter worth $934,000. FMR LLC bought a new position in Aerpio Pharmaceuticals during the 2nd quarter worth $3,648,000. Finally, Nexthera Capital LP bought a new position in Aerpio Pharmaceuticals during the 2nd quarter worth $1,240,000. Hedge funds and other institutional investors own 0.37% of the company’s stock.
Shares of ARPO stock opened at $2.08 on Friday. Aerpio Pharmaceuticals Inc has a 1 year low of $1.75 and a 1 year high of $5.50.
In other Aerpio Pharmaceuticals news, CEO Stephen J. Hoffman purchased 31,967 shares of Aerpio Pharmaceuticals stock in a transaction on Monday, November 12th. The stock was bought at an average price of $2.01 per share, for a total transaction of $64,253.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Muneer A. Satter purchased 60,000 shares of Aerpio Pharmaceuticals stock in a transaction on Thursday, December 6th. The shares were acquired at an average price of $2.09 per share, with a total value of $125,400.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 151,967 shares of company stock valued at $308,454 in the last quarter. 38.60% of the stock is currently owned by insiders.
A number of research analysts recently commented on the company. HC Wainwright set a $9.00 price objective on Aerpio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research downgraded Aerpio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Finally, Guggenheim assumed coverage on Aerpio Pharmaceuticals in a research note on Wednesday, September 19th. They set a “buy” rating and a $10.00 price objective for the company.
Aerpio Pharmaceuticals Profile
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Read More: Swap
Want to see what other hedge funds are holding ARPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO).
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.